shares of Apellis Pharmaceuticals Inc (APLS) on
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which develops novel therapeutic compounds. The company is headquartered in Waltham, Massachusetts and currently employs 87 full-time employees. The firm focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The firm’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company’s lead product candidate is APL-2. APL-2 is Phase III clinical trials developed for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. The firm is developing APL-9 for intravenous administration in systemic indications.